HEPCINAT PLUS TABS 1X28 TAB.

About

Hepcinat Plus, a fixed-dose combination of sofosbuvir and ledipasvir, is a highly effective direct-acting antiviral (DAA) medication for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is an NS5B polymerase inhibitor, and ledipasvir is an NS5A inhibitor. This combination targets two different viral proteins, leading to potent inhibition of HCV replication and high sustained virologic response rates across various genotypes, particularly genotypes 1, 4, 5, and 6. It is indicated for patients with or without cirrhosis, and in some cases, with ribavirin for decompensated cirrhosis, providing a comprehensive and curative treatment option. The typical treatment duration is 8 or 12 weeks, offering a streamlined and highly successful approach to HCV eradication.

Uses

• Chronic hepatitis C virus (HCV) infection.
• HCV genotypes 1, 4, 5, and 6.
• HCV with compensated cirrhosis.
• HCV with decompensated cirrhosis (with ribavirin).

Directions For Use

Take one tablet orally once daily with or without food.

Benefits

• High sustained virologic response (SVR) rates.
• Effective for multiple HCV genotypes.
• Convenient once-daily dosing.
• Well-tolerated with minimal side effects.
• Suitable for patients with cirrhosis.
• Short treatment duration (8-12 weeks).

Side Effects

• Headache
• Fatigue
• Nausea
• Diarrhea
• Insomnia
• Anemia (if with ribavirin)
• Rash
• Irritability
• Dizziness
• Bradycardia (with amiodarone)
• Elevated bilirubin (rare)
• Pancreatitis (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it can worsen liver disease and interfere with treatment.
• Pregnancy - Not recommended; use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - Not recommended due to potential for serious adverse effects in the infant.
• Liver - Use with caution in decompensated cirrhosis; monitor closely for liver function.
• Kidney - No dosage adjustment needed for mild to severe renal impairment, but not studied in ESRD on dialysis.
• Lung - No specific contraindication; generally safe for use in patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.